Format

Send to

Choose Destination
Nat Cell Biol. 2017 Oct 31;19(11):1309-1310. doi: 10.1038/ncb3638.

PARPi focus the spotlight on replication fork protection in cancer.

Author information

1
Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

Abstract

PARP inhibitors (PARPi) kill BRCA1/2-mutated cancers, which become resistant when DNA repair functions are restored. Now, MUS81 nuclease inhibition due to EZH2 downregulation is found to restore DNA replication fork protection but not repair, leading to PARPi-resistance in mutant BRCA2 cells and patients. This challenges the DNA repair dominance in synthetic lethality.

PMID:
29087384
DOI:
10.1038/ncb3638
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center